MX2023002417A - Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. - Google Patents

Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.

Info

Publication number
MX2023002417A
MX2023002417A MX2023002417A MX2023002417A MX2023002417A MX 2023002417 A MX2023002417 A MX 2023002417A MX 2023002417 A MX2023002417 A MX 2023002417A MX 2023002417 A MX2023002417 A MX 2023002417A MX 2023002417 A MX2023002417 A MX 2023002417A
Authority
MX
Mexico
Prior art keywords
cell culture
asparagine
mitigate
fed
sequence variants
Prior art date
Application number
MX2023002417A
Other languages
English (en)
Spanish (es)
Inventor
Amy S Johnson
Sandra Bennun-Serrano
Shawn M Lawrence
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023002417A publication Critical patent/MX2023002417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/20—Aspartic acid; Asparagine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023002417A 2020-08-31 2021-08-27 Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. MX2023002417A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072740P 2020-08-31 2020-08-31
US202063072745P 2020-08-31 2020-08-31
PCT/US2021/047870 WO2022047108A1 (en) 2020-08-31 2021-08-27 Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants

Publications (1)

Publication Number Publication Date
MX2023002417A true MX2023002417A (es) 2023-03-22

Family

ID=78073988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002417A MX2023002417A (es) 2020-08-31 2021-08-27 Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.

Country Status (14)

Country Link
US (2) US12163122B2 (enExample)
EP (1) EP4204578A1 (enExample)
JP (1) JP2023542820A (enExample)
KR (1) KR20230058094A (enExample)
CN (1) CN116209772A (enExample)
AU (1) AU2021332355A1 (enExample)
BR (1) BR112023003273A2 (enExample)
CA (1) CA3192999A1 (enExample)
CL (1) CL2023000576A1 (enExample)
CO (1) CO2023003662A2 (enExample)
IL (1) IL300828A (enExample)
MX (1) MX2023002417A (enExample)
TW (1) TW202432837A (enExample)
WO (1) WO2022047108A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901794B (zh) 2019-11-15 2026-05-01 隆萨有限公司 用于生产接种物的过程和系统
CN114836367A (zh) * 2022-04-28 2022-08-02 上海东富龙生物试剂有限公司 用于hek293细胞培养及腺病毒、腺相关病毒复制扩增的化学成分限定培养基

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
DE3271210D1 (en) 1981-12-24 1986-06-19 Asahi Chemical Ind Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7429491B2 (en) 2003-05-15 2008-09-30 Wyeth Restricted glucose feed for animal cell culture
EP1664283A4 (en) 2003-09-18 2007-12-26 Raven Biotechnologies Inc CELL CULTURE MEDIA
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
KR101662412B1 (ko) * 2011-07-01 2016-10-04 암젠 인크 포유동물 세포 배양
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
US10526631B1 (en) * 2016-03-15 2020-01-07 Ares Trading S.A. Method of reducing serine for asparagine misincorporation

Also Published As

Publication number Publication date
WO2022047108A1 (en) 2022-03-03
BR112023003273A2 (pt) 2023-05-02
IL300828A (en) 2023-04-01
CA3192999A1 (en) 2022-03-03
US12163122B2 (en) 2024-12-10
US20250066718A1 (en) 2025-02-27
JP2023542820A (ja) 2023-10-12
CL2023000576A1 (es) 2023-09-29
CO2023003662A2 (es) 2023-04-05
EP4204578A1 (en) 2023-07-05
US20220064591A1 (en) 2022-03-03
KR20230058094A (ko) 2023-05-02
TW202432837A (zh) 2024-08-16
TW202225398A (zh) 2022-07-01
AU2021332355A1 (en) 2023-03-23
CN116209772A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
Okoro et al. Microalgae cultivation and harvesting: Growth performance and use of flocculants-A review
CL2023000576A1 (es) Estrategias de suministro con asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
ATE488600T1 (de) Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
MX2012006777A (es) Uso de promotores inducibles en la produccion de metionina.
NZ586250A (en) Cell culture processes
WO2021097452A3 (en) Biosynthetic production of psilocybin and related intermediates in recombinant organisms
MY166543A (en) A microorganism for methionine production with enhanced glucose import
MX352746B (es) Aceites específicos producidos a partir de microorganismos heterótrofos recombinantes.
BRPI0409895B8 (pt) método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células
MX2023002502A (es) Microorganismos productores de l-valina y metodo de produccion de l-valina que utiliza los mismos.
CA3241931A1 (en) Methods and systems for optimizing culture conditions in a culture process
MX2021016018A (es) Métodos de fermentación optimizada de euglena que utilizan diseño de tanque modificado.
EP4368699A3 (en) Methods of producing recombinant proteins
MX2022012829A (es) Metodo para tratamiento de medio antes de inoculacion.
Clarens et al. Kinetic studies of acetate fermentation by Methanosarcina sp. MSTA-1
MX2025006558A (es) Tratamiento con insulina para mejorar la genomanipulacion de linfocitos t
WO2025185594A8 (zh) 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法
PH12019500184B1 (en) Method for producing ethanol
WO2021016489A3 (en) Fibrosis-specific cell culture substrate and methods of use
MY159592A (en) Fermentative production of methionine hydroxy analog (mha)
Armshaw et al. Optimisation of ethanol production in Synechocystis PCC 6803, the DEMA approach
NZ594505A (en) Enzyme-based fed-batch technique in liquid cultures
PH12018502640A1 (en) A recombinant yeast and a method for producing ethanol using the same
Vergara et al. Metabolic behavior of CHO cells cultured in perfusion with handling simultaneous of low temperature and source of carbon
Da Silva et al. Production of citric acid by Yarrowia lipolytica using glycerol as carbon source